VANCOUVER, BC, June 24, 2021 /CNW/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSXV: NUMI), a mental health
care company advancing innovative treatments and safe,
evidence-based psychedelic-assisted therapies, announces that it
has granted 1,825,000 incentive stock options (the
"Options") to directors, officers and employees of the
Company, which are subject to regulatory approval.
Of the 1,825,000 Options granted during the month of May,
810,000 were issued to directors and an officer of Numinus, which
have an exercise price of $0.90 per
common share and are exercisable until May
19, 2023. The 1,015,000 Options issued to employees have
exercise prices ranging between $0.87
and $1.00 with expiry dates ranging
from May 1, 2023 to May 17, 2023.
The Company's Stock Option Plan allows for the issuance of up to
10% of issued and outstanding share capital in the form of
incentive stock options. As the result of the above grants, the
Company has 8,931,500 options issued, representing approximately
4.42% of the issued and outstanding share capital.
About Numinus
Numinus Wellness (TSX-V: NUMI) empowers
people to heal and be well through the development and delivery of
innovative mental health care and access to safe, evidence-based
psychedelic-assisted therapies. The Numinus Wellness model -
including psychedelic production, research and clinic care
- is at the forefront of a transformation aimed at healing
rather than managing symptoms for depression, anxiety, trauma, pain
and substance abuse. At Numinus, we are leading the integration of
psychedelic-assisted therapies into mainstream clinical practice,
and building the foundation for a healthier society.
Learn more at numinus.ca, and follow us on Facebook, Twitter,
and Instagram.
Forward-Looking Statements
This news release
contains forward-looking statements within the meaning of
applicable securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements". Forward-looking statements can be
identified by the use of words such as "plans", "expects" or "does
not expect", "is expected", "estimates", "intends", "anticipates"
or "does not anticipate", or "believes", or variations of such
words and phrases or statements that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, among others, dependence on obtaining and
maintaining regulatory approvals, including acquiring and renewing
federal, provincial, municipal, local or other licences and any
inability to obtain all necessary governmental approvals, licences
and permits to operate and expand the Company's facilities;
regulatory or political change such as changes in applicable laws
and regulations, including federal and provincial legalization of
psychedelic therapies, due to inconsistent public opinion,
perception of the medical-use of psychedelics, delays or
inefficiencies or any other reasons; any other factors or
developments which may hinder market growth; the Company's limited
operating history and lack of historical profits; reliance on
management; the Company's requirements for additional financing,
and the effect of capital market conditions and other factors on
capital availability; competition, including from more established
or better financed competitors; the need to secure and maintain
corporate alliances and partnerships, including with research and
development institutions, customers and suppliers; the development
and implementation of medical protocols and treatment standard
operating procedures for the use of psychedelic therapies; the
Company's goals to develop and implement partnerships with research
organizations and other key players in the integrative mental
health industry; the Company's ability to successfully withstand
the economic impact of COVID-19; the medical benefits, safety,
efficacy, dosing and social acceptance of psychedelics; the
approval and/or success of compassionate access clinical trials;
the cultivation and harvest of Psilocybe mushrooms; and the
availability of trained personnel and medical professionals. These
factors should be considered carefully, and readers are cautioned
not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other risk factors that cause actions,
events or results to differ from those anticipated, estimated or
intended. There can be no assurance that forward-looking statements
will prove to be accurate, as actual results and future events
could differ materially from those anticipated in forward-looking
statements. The Company has no obligation to update any
forward-looking statement, even if new information becomes
available as a result of future events, new information or for any
other reason except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/numinus-announces-grant-of-stock-options-301319875.html
SOURCE Numinus Wellness Inc.